Stock price of Genzyme spiked on the news that  FDA granted approval to  Lumizymethel (aglucosidase alfa) for the treatment of late onset Pompe disease. Pompe disease is a rare  and often fatal condition that disables the heart and muscles due to deficiency of an enzyme called alpha-glucosidase (GAA). Lumizyme, marketed outside the US as Myozyme is approved for the treatment of Pompe disease in about 45 countries  and is available in the US for the treatment of infants and children. Approval of Lumizymethe was expected on Jun 17, 2010. The only surprise was that the approval came  about three weeks early.  The strong up move in the stock price apparantley was the result of investors

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .

www.thearorareport.com THE ARORA REPORT, Ltd. HOME OF THE UNIQUE ZYX CHANGE METHOD DEDICATED SOLELY TO PROFIT FROM CHANGE BY TRADING AND INVESTING VERIFIABLE PERFORMANCE RECORD Every closed trade since 2007, without exception, is included in the performance results. Number of winning positions: 162 Number of losing positions: 10 Average annualized % return per position: 296.77% ………………Check out details .